![MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value | Acta Neuropathologica Communications | Full Text MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value | Acta Neuropathologica Communications | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40478-023-01622-w/MediaObjects/40478_2023_1622_Fig1_HTML.png)
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value | Acta Neuropathologica Communications | Full Text
![Frontiers | Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications Frontiers | Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications](https://www.frontiersin.org/files/Articles/590648/fonc-10-590648-HTML/image_m/fonc-10-590648-g001.jpg)
Frontiers | Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications
![JPM | Free Full-Text | Machine Learning and Radiomic Features to Predict Overall Survival Time for Glioblastoma Patients JPM | Free Full-Text | Machine Learning and Radiomic Features to Predict Overall Survival Time for Glioblastoma Patients](https://pub.mdpi-res.com/jpm/jpm-11-01336/article_deploy/html/images/jpm-11-01336-ag-550.jpg?1639358743)
JPM | Free Full-Text | Machine Learning and Radiomic Features to Predict Overall Survival Time for Glioblastoma Patients
![Frontiers | The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma Frontiers | The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma](https://www.frontiersin.org/files/Articles/447805/fphar-10-00200-HTML/image_m/fphar-10-00200-g001.jpg)
Frontiers | The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma
![Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419) - European Journal of Cancer Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419) - European Journal of Cancer](https://www.ejcancer.com/cms/asset/35d910ec-c63d-4c2c-9ec3-fc203f29cdfb/gr1.jpg)
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419) - European Journal of Cancer
![Cancers | Free Full-Text | Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM) Cancers | Free Full-Text | Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)](https://pub.mdpi-res.com/cancers/cancers-15-02116/article_deploy/html/images/cancers-15-02116-ag.png?1680840824)
Cancers | Free Full-Text | Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
![PDF) Long-term survival in glioblastoma: Methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor PDF) Long-term survival in glioblastoma: Methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor](https://www.researchgate.net/profile/Mara-Popovic/publication/284122057/figure/fig3/AS:670442431979523@1536857340113/Survival-of-glioblastoma-patients_Q320.jpg)
PDF) Long-term survival in glioblastoma: Methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor
![Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics | Acta Neurochirurgica Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics | Acta Neurochirurgica](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00701-023-05544-3/MediaObjects/701_2023_5544_Fig2_HTML.png)
Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics | Acta Neurochirurgica
![Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma | Scientific Reports Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-017-18310-0/MediaObjects/41598_2017_18310_Fig1_HTML.jpg)
Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma | Scientific Reports
![Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis | Scientific Reports Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-68011-4/MediaObjects/41598_2020_68011_Fig1_HTML.png)
Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis | Scientific Reports
![First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide | Journal of Neuro-Oncology First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide | Journal of Neuro-Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs11060-019-03339-0/MediaObjects/11060_2019_3339_Fig1_HTML.png)
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide | Journal of Neuro-Oncology
![Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy | Scientific Reports Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-67697-w/MediaObjects/41598_2020_67697_Fig1_HTML.png)
Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy | Scientific Reports
![Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma | Radiation Oncology | Full Text Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma | Radiation Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13014-019-1272-6/MediaObjects/13014_2019_1272_Fig1_HTML.png)